In many randomized clinical trials of therapeutics for COVID-19, the primary outcome is an ordinal categorical variable, and interest focuses on the odds ratio (active agent vs. control) under the assumption of a proportional odds model. Although at the final analysis the outcome will be determined for all subjects, at an interim analysis, the status of some participants may not yet be determined, e.g., because ascertainment of the outcome may not be possible until some pre-specified follow-up time. Accordingly, the outcome from these subjects can be viewed as censored. A valid interim analysis can be based on data only from those subjects with full follow up; however, this approach is inefficient, as it does not exploit additional information that may be available on those for whom the outcome is not yet available at the time of the interim analysis. Appealing to the theory of semiparametrics, we propose an estimator for the odds ratio in a proportional odds model with censored, time-lagged categorical outcome that incorporates additional baseline and time-dependent covariate information and demonstrate that it can result in considerable gains in efficiency relative to simpler approaches. A byproduct of the approach is a covariate-adjusted estimator for the odds ratio based on the full data that would be available at a final analysis.
翻译:在对COVID-19治疗方法的许多随机临床试验中,主要结果是一个绝对的随机性变数,兴趣集中在假设比例差数模型下的概率比(活性剂对控制)上,尽管在最后分析时,将确定所有科目的结果,但在临时分析中,一些参与者的地位可能尚未确定,例如,由于在事先确定的后续行动时间之前可能无法确定结果,因此,可以将这些主题的结果视为审查的结果。有效的临时分析只能以那些完全跟踪的科目的数据为基础;然而,这种办法效率低,因为它没有利用在临时分析时尚未获得结果的那些科目可能掌握的其他资料。我们建议,根据半参数理论,在一种有审查、时间滞后的绝对结果中,在一种相称的模型中,对概率比作一个估计,该模型将纳入额外的基线和基于时间的共变数信息,并表明它能够比较简单的方法取得相当大的效率;但是,这种办法是无效的,因为它没有利用在临时分析时尚未获得结果的人可能掌握的其他资料。